Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

Core Insights - Viva Biotech reported a revenue of RMB1,729.4 million for 2025, with a net profit of RMB269.3 million, reflecting a year-on-year increase of 21.3% [1][2] - The company emphasized its leadership in AI-driven drug discovery and the successful scale-up of its CDMO commercial products [1][5] Financial Performance - Revenue reached RMB1,729.4 million, with a gross profit of RMB655.6 million and a gross profit margin of 37.9%, up 3.3 percentage points year-on-year [1] - Net profit increased to RMB269.3 million, a 21.3% rise from RMB220.0 million in the previous year [1] - Adjusted non-IFRS net profit was RMB335.3 million, marking a 6.6% increase from RMB314.6 million [1] CRO Business Growth - Revenue from the CRO business grew to RMB848.6 million, a 4.7% increase from RMB810.9 million [2] - Adjusted gross profit for the CRO segment rose to RMB383.1 million, reflecting a 7.3% increase [2] - The total number of CRO clients reached 1,866, with top ten clients contributing 25.7% of total revenue [2] AI-Driven Drug Discovery - The company delivered over 98,885 protein structures, with 16,169 newly delivered in 2025 [3] - Revenue from novel molecular modalities accounted for 15.8% of total CRO revenue, showing an 11.0% year-on-year increase [3] - AI-enabled projects contributed approximately 12.0% of total CRO revenue, with 196 projects supported by AIDD [4] CDMO Business Developments - Two new CDMO commercial projects were launched, expected to drive future growth [5] - Langhua Pharmaceutical generated revenue of RMB880.8 million, with a 100% retention rate for its top ten clients [7] - The company is expanding production capacity, with an additional 400 cubic meters under construction [7] Incubation Portfolio Success - The company realized investment income of nearly RMB83.6 million from exits of incubation portfolio companies [8] - A total of 93 start-ups were incubated, with 19 projects achieving full or partial exits [8] - The incubation companies have 231 pipelines under research, with 44 at the clinical stage [8] Workforce and Facilities - As of December 31, 2025, the company employed 2,169 staff, including 1,123 in CRO R&D [9] - The company is expanding its facilities to meet growing business demands [9]